Donel M Martin1, Shawn M McClintock2,3, Jane J Forster1, Tin Yan Lo1, Colleen K Loo1. 1. School of Psychiatry, Black Dog Institute, University of New South Wales, Sydney, Australia. 2. Neurocognitive Research Laboratory, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.
Abstract
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) is an approved therapeutic treatment of major depressive disorder and has increasing clinical use throughout the world. However, it remains unclear whether an rTMS course for depression may also produce cognitive enhancement. In a recent meta-analysis of sham-controlled randomized controlled studies (RCTs) conducted in patients with neuropsychiatric conditions, no evidence was found for generalized cognitive enhancing effects across cognitive domains with active compared to sham rTMS. Notwithstanding, there remains the possibility of cognitive effects following an rTMS course that are more highly specific, for example, in specific clinical conditions, or at the individual task level. This study aimed to determine whether a therapeutic rTMS course in patients with depression is associated with cognitive enhancing effects at the task level. METHODS: A systematic review and meta-analysis of outcomes on individual neuropsychological tasks from sham-controlled RCTs where an rTMS course was administered to the dorsolateral prefrontal cortex (DLPFC) in patients with depression. RESULTS: Eighteen studies met the inclusion criteria. Active rTMS treatment showed no specific enhancing effects on the majority of cognitive tasks. Modest effect size improvements with active compared to sham rTMS treatment were found for performance on the Trail Making Test Parts A (g = 0.28, 95% CI = 0.06-0.50) and B (g = 0.26, 95% CI = 0.06-0.47). CONCLUSION: A therapeutic rTMS course administered to the prefrontal cortex for depression may produce modest cognitive enhancing effects specific to psychomotor speed, visual scanning, and set-shifting ability.
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) is an approved therapeutic treatment of major depressive disorder and has increasing clinical use throughout the world. However, it remains unclear whether an rTMS course for depression may also produce cognitive enhancement. In a recent meta-analysis of sham-controlled randomized controlled studies (RCTs) conducted in patients with neuropsychiatric conditions, no evidence was found for generalized cognitive enhancing effects across cognitive domains with active compared to sham rTMS. Notwithstanding, there remains the possibility of cognitive effects following an rTMS course that are more highly specific, for example, in specific clinical conditions, or at the individual task level. This study aimed to determine whether a therapeutic rTMS course in patients with depression is associated with cognitive enhancing effects at the task level. METHODS: A systematic review and meta-analysis of outcomes on individual neuropsychological tasks from sham-controlled RCTs where an rTMS course was administered to the dorsolateral prefrontal cortex (DLPFC) in patients with depression. RESULTS: Eighteen studies met the inclusion criteria. Active rTMS treatment showed no specific enhancing effects on the majority of cognitive tasks. Modest effect size improvements with active compared to sham rTMS treatment were found for performance on the Trail Making Test Parts A (g = 0.28, 95% CI = 0.06-0.50) and B (g = 0.26, 95% CI = 0.06-0.47). CONCLUSION: A therapeutic rTMS course administered to the prefrontal cortex for depression may produce modest cognitive enhancing effects specific to psychomotor speed, visual scanning, and set-shifting ability.
Authors: Paul B Fitzgerald; Kate E Hoy; David Elliot; R N Susan McQueen; Lenore E Wambeek; Zafiris J Daskalakis Journal: Neuropsychopharmacology Date: 2018-02-05 Impact factor: 7.853
Authors: Sydney S Cash; Alik S Widge; Ishita Basu; Ali Yousefi; Britni Crocker; Rina Zelmann; Angelique C Paulk; Noam Peled; Kristen K Ellard; Daniel S Weisholtz; G Rees Cosgrove; Thilo Deckersbach; Uri T Eden; Emad N Eskandar; Darin D Dougherty Journal: Nat Biomed Eng Date: 2021-11-01 Impact factor: 29.234
Authors: Chris Baeken; Anna-Katharine Brem; Martijn Arns; Andre R Brunoni; Igor Filipčić; Ana Ganho-Ávila; Berthold Langguth; Frank Padberg; Emmanuel Poulet; Fady Rachid; Alexander T Sack; Marie-Anne Vanderhasselt; Djamila Bennabi Journal: Curr Opin Psychiatry Date: 2019-09 Impact factor: 4.741
Authors: Jakub Antczak; Katarzyna Kowalska; Aleksandra Klimkowicz-Mrowiec; Barbara Wach; Katarzyna Kasprzyk; Marta Banach; Karolina Rzeźnicka-Brzegowy; Jadwiga Kubica; Agnieszka Słowik Journal: Neuropsychiatr Dis Treat Date: 2018-03-13 Impact factor: 2.570
Authors: Lucas Borrione; Helena Bellini; Lais Boralli Razza; Ana G Avila; Chris Baeken; Anna-Katharine Brem; Geraldo Busatto; Andre F Carvalho; Adam Chekroud; Zafiris J Daskalakis; Zhi-De Deng; Jonathan Downar; Wagner Gattaz; Colleen Loo; Paulo A Lotufo; Maria da Graça M Martin; Shawn M McClintock; Jacinta O'Shea; Frank Padberg; Ives C Passos; Giovanni A Salum; Marie-Anne Vanderhasselt; Renerio Fraguas; Isabela Benseñor; Leandro Valiengo; Andre R Brunoni Journal: Braz J Psychiatry Date: 2020-03-16 Impact factor: 2.697